Profit before interest, taxes and amortization: Immutep (IMMP)

Operating profit before depreciation on GURU.Markets reflects a financial trend where the 0.00 level serves as a critical mark. Immutep Limited (IMMP) develops advanced LAG-3 protein methods to activate immunity against tumors. The company is currently scaling its portfolio of innovative combinations within clinical trials. In the future, the licensing of molecules will ensure low production costs and colossal margin growth.

IMMP Immutep Operating profit EBITDA (11/23/2025 - 11/10/2026)

Immutep (IMMP) - metric breakdowns and financial figures

- current quotes and average value forecast:

Stock Quotes Immutep Corp|IMMP - Price Target Chart

- company stock exchange capitalization indicators:

Market Value Immutep|IMMP - Total Company Value

- book capitalization data:

Accounting Value per Share Immutep|IMMP - Book Capitalization|Market-to-Book Ratio immutep.com|IMMP - Aggregate Company Assets

- debt level and financial liquidity data:

- earnings and multiples data:

IMMP - Net Income|Future Net Profit Immutep Limited|IMMP - P/E Multiple|Projected Price to Earnings Ratio immutep.com|IMMP - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Immutep|IMMP - Operating profit before deduction of amortization|Earnings per share for the trailing year Immutep|IMMP - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months immutep.com|IMMP - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Immutep Limited

Analysis of all company metrics:IMMP - Immutep Corp

Flagship merchandise of Immutep Limited ADR

Long-term risk control requires an analysis of cash flow stability, which allows for an assessment of the business's actual viability regardless of accounting accruals. By relying on operating profit dynamics, an investor can see the daily cash balance after deducting operating expenses, which for Immutep Limited (IMMP) is sustained through strategic alliances in the LAG-3 field, confirming the fundamental value of its developments.

Competitors of Immutep Limited (IMMP)

MRUS - Operating profit before deduction of amortization|ANIX - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization atossatherapeutics.com|contexttherapeutics.com (CNTX) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Mersana Therapeutics, Inc.|BCTX (BriaCell Therapeutics Corp) - Operating profit EBITDA|Profit before interest, taxes and amortization ESSA Pharma Inc EPIX|Profit before payment of interest, taxes and amortization QT Imaging Holdings, Inc. (QTI)